Pandemic influenza vaccine development: Time is of the essence

Expert Review of Vaccines

Volumn 5, Issue 5, 2006, Pages 603-606

  Cox, Rebecca J ^a   Brokstad, Karl A ^a   Haaheim, Lars R ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; AVIAN INFLUENZA VACCINE; BACULOVIRUS VACCINE; DNA VACCINE; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; SUBUNIT VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADJUVANT THERAPY; AVIAN INFLUENZA; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENTIATION; DRUG SAFETY; EDITORIAL; HEALTH CARE SYSTEM; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; INFLUENZA VIRUS C; MORTALITY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; VACCINATION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ADJUVANTS, IMMUNOLOGIC; DISEASE OUTBREAKS; DRUG DESIGN; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; TIME FACTORS; WORLD HEALTH;

EID: 33845880641     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.5.603     Document Type: Editorial

References (12)

1. Cox RJ, Brokstad KA, Ogra PL. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines Scand. J. Immunol. 59(1), 1-15 (2004).
2. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13-14), 1732-1737 (2001).
3. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
4. Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367(9523), 1657-1664 (2006).
5. Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a Phase I randomised controlled trial. Lancet 368 (9540) 991-997 (2006).
6. Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med. Microbiol. Immunol.(Berl.) 191(3-4), 203-208 (2002).
7. Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet 357(9272), 1937-1943 (2001).
8. Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191(8), 1210-1215 (2005).
9. Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351(22), 2286-2294 (2004).
10. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351(22), 2295-2301 (2004).
11. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10), 1157-1163 (1999).
12. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24(21), 4475-4481 (2006).